文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

鸢尾素与脓毒症生存相关,并通过AMPK信号减轻巨噬细胞促炎反应

Irisin is associated with survival in sepsis and attenuates macrophage pro-inflammatory responses with involvement of AMPK signaling.
PubMed 文献 · Shock · 2026-10-19
一句话结论脓毒症患者血清鸢尾素较高与30天死亡率降低独立相关(aHR 0.955),但单独判别能力有限(AUROC 0.609)。

本研究在655例前瞻性脓毒症注册队列中评估鸢尾素与30天死亡率的独立关联,并用体外巨噬细胞和CLP小鼠模型探讨机制。结果显示,血清鸢尾素较高与30天死亡率降低独立相关(aHR 0.955,95%CI 0.913-0.999,p=0.044),但单独判别能力有限(AUROC 0.609),与乳酸(AUROC 0.652)无显著差异(p=0.145)。体外鸢尾素抑制LPS诱导的促炎细胞因子产生、维持AMPK磷酸化、减少IκBα降解,部分效应在AMPKα1敲低后减弱。CLP小鼠中鸢尾素改善7天生存(75% vs 36%,p<0.05)并降低24小时全身炎症细胞因子。

要点

  • 脓毒症患者血清鸢尾素较高与30天死亡率降低独立相关(aHR 0.955,95%CI 0.913-0.999,p=0.044,N=655)。
  • 鸢尾素对30天死亡的单独判别能力有限(AUROC 0.609),与乳酸(AUROC 0.652)无显著差异(p=0.145)。
  • 体外鸢尾素抑制LPS诱导的巨噬细胞促炎细胞因子产生,维持AMPK磷酸化并减少IκBα降解。
  • CLP小鼠中鸢尾素改善7天生存(75% vs 36%,p<0.05)并降低24小时全身炎症细胞因子。
  • 部分细胞效应在AMPKα1敲低后减弱,提示AMPK信号参与鸢尾素的部分免疫调节作用。

适用人群与场景

  • 前瞻性收集的脓毒症注册队列与生物样本库中的脓毒症患者(N=655)
  • 机制研究使用体外巨噬细胞和CLP小鼠模型
  • 原文未提及急诊/ICU/院前场景或病情阶段的限定

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:前瞻性脓毒症注册队列(N=655)结合体外巨噬细胞实验和CLP小鼠模型
  • 主要终点:血清鸢尾素较高与30天死亡率降低独立相关(aHR 0.955,95%CI 0.913-0.999,p=0.044)
  • 判别能力:鸢尾素AUROC 0.609,乳酸AUROC 0.652,两者无显著差异(p=0.145)
  • 体外:鸢尾素抑制LPS诱导的促炎细胞因子产生,维持AMPK磷酸化,减少IκBα降解,降低巨噬细胞促炎标志物;部分效应在AMPKα1敲低后减弱
  • 体内:CLP小鼠鸢尾素改善7天生存(75% vs 36%,p<0.05),降低24小时全身炎症细胞因子

证据类型、等级与局限

  • 证据类型:前瞻性队列研究联合体外和动物实验
  • 局限:鸢尾素单独判别能力有限(AUROC 0.609);机制研究为体外和动物模型,需进一步验证;原文未提及证据等级或推荐强度

对床旁实践的改变

  • 支持将鸢尾素作为脓毒症整合性预后评估的一部分进一步研究,但单独判别能力有限,不能替代乳酸等现有指标
  • 鸢尾素相关AMPK信号通路为脓毒症免疫调节提供研究方向,尚未转化为床旁治疗推荐

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is a leading cause of morbidity and mortality, yet effective targeted therapies remain limited. We evaluated the prognostic significance of irisin, a myokine, in sepsis cohort and examined its immunomodulatory effects on macrophages using a translational approach.

METHODS: Patients were enrolled in a prospectively collected sepsis registry and biobank. Multivariable Cox proportional hazards model was conducted to assess independent association between irisin and 30-day mortality. Mechanistic studies used macrophages ex vivo and a murine cecal ligation and puncture (CLP) model.

RESULTS: Higher serum irisin was independently associated with lower 30-day mortality (adjusted hazard ratio 0.955, 95% confidence interval 0.913-0.999, p=0.044) in patients with sepsis (N=655). Irisin showed modest discrimination for 30-day mortality (AUROC 0.609), with no statistically significant difference from lactate (AUROC 0.652; p=0.145). In vitro , irisin suppressed LPS-induced pro-inflammatory cytokine production, preserved AMPK phosphorylation, attenuated IκBα degradation, and reduced pro-inflammatory markers in macrophages. Several of these cellular effects were attenuated following AMPKα1 depletion. In vivo , irisin improved 7-day survival after CLP (75% vs. 36%, p<0.05) and reduced systemic inflammatory cytokines at 24 hours.

CONCLUSIONS: Higher serum irisin was independently associated with lower 30-day mortality in patients with sepsis, although its standalone discriminatory performance was modest. Experimental findings further showed that irisin improved survival and attenuated macrophage inflammatory responses, with AMPK signaling contributing to several cellular effects. These findings support further evaluation of irisin as part of integrated prognostic assessment and investigation of irisin-related signaling in sepsis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Ahn S, Jeon JH, Jung M, et al. Irisin is associated with survival in sepsis and attenuates macrophage pro-inflammatory responses with involvement of AMPK signaling. Shock. 2026. PMID: 42873095. doi:10.1097/SHK.0000000000002946

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。